129 related articles for article (PubMed ID: 7837110)
1. Actinomycin D for reinduction of remission in dogs with resistant lymphoma.
Moore AS; Ogilvie GK; Vail DM
J Vet Intern Med; 1994; 8(5):343-4. PubMed ID: 7837110
[TBL] [Abstract][Full Text] [Related]
2. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006).
Bannink EO; Sauerbrey ML; Mullins MN; Hauptman JG; Obradovich JE
J Am Vet Med Assoc; 2008 Aug; 233(3):446-51. PubMed ID: 18673031
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.
Siedlecki CT; Kass PH; Jakubiak MJ; Dank G; Lyons J; Kent MS
Can Vet J; 2006 Jan; 47(1):52-9. PubMed ID: 16536229
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.
Alvarez FJ; Kisseberth WC; Gallant SL; Couto CG
J Vet Intern Med; 2006; 20(5):1178-83. PubMed ID: 17063713
[TBL] [Abstract][Full Text] [Related]
5. Treatment of tumor-bearing dogs with actinomycin D.
Hammer AS; Couto CG; Ayl RD; Shank KA
J Vet Intern Med; 1994; 8(3):236-9. PubMed ID: 8064663
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma.
Khanna C; Lund EM; Redic KA; Hayden DW; Bell FW; Goulland EL; Klausner JS
J Am Vet Med Assoc; 1998 Oct; 213(7):985-90. PubMed ID: 9776993
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
Simon D; Moreno SN; Hirschberger J; Moritz A; Kohn B; Neumann S; Jurina K; Scharvogel S; Schwedes C; Reinacher M; Beyerbach M; Nolte I
J Am Vet Med Assoc; 2008 Mar; 232(6):879-85. PubMed ID: 18341445
[TBL] [Abstract][Full Text] [Related]
8. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma.
Zemann BI; Moore AS; Rand WM; Mason G; Ruslander DM; Frimberger AE; Wood CA; L'Heureux DA; Gliatto J; Cotter SM
J Vet Intern Med; 1998; 12(6):465-70. PubMed ID: 9857340
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of mitoxantrone for the treatment of lymphoma in dogs.
Moore AS; Ogilvie GK; Ruslander D; Rand WS; Cotter SM; Getzy DM; L'Heureux DA; Dennis RA
J Am Vet Med Assoc; 1994 Jun; 204(12):1903-5. PubMed ID: 8077132
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Valerius KD; Ogilvie GK; Fettman MJ; Walton JA; Richardson K; Powers BE; McNiel EA; Rogers QR
J Am Vet Med Assoc; 1999 Feb; 214(3):353-6. PubMed ID: 10023395
[TBL] [Abstract][Full Text] [Related]
11. Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs.
Zenker I; Meichner K; Steinle K; Kessler M; Hirschberger J
Vet Rec; 2010 Nov; 167(19):744-8. PubMed ID: 21257510
[TBL] [Abstract][Full Text] [Related]
12. Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma?
Hahn KA; Richardson RC; Teclaw RF; Cline JM; Carlton WW; DeNicola DB; Bonney PL
J Vet Intern Med; 1992; 6(1):3-10. PubMed ID: 1548624
[TBL] [Abstract][Full Text] [Related]
13. Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs.
Ogilvie GK; Vail DM; Klein MK; Powers BE; Dickinson K
J Am Vet Med Assoc; 1991 May; 198(10):1762-4. PubMed ID: 2071476
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs.
Mutsaers AJ; Glickman NW; DeNicola DB; Widmer WR; Bonney PL; Hahn KA; Knapp DW
J Am Vet Med Assoc; 2002 Jun; 220(12):1813-7. PubMed ID: 12092954
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.
Parsons-Doherty M; Poirier VJ; Monteith G
Can Vet J; 2014 Feb; 55(2):175-80. PubMed ID: 24489398
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
Wang SL; Lee JJ; Liao AT
Vet J; 2015 Jul; 205(1):69-73. PubMed ID: 26004824
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma.
Keller ET; MacEwen EG; Rosenthal RC; Helfand SC; Fox LE
J Vet Intern Med; 1993; 7(5):289-95. PubMed ID: 8263847
[TBL] [Abstract][Full Text] [Related]
18. Histologic classification as an indication of therapeutic response in malignant lymphoma of dogs.
Gray KN; Raulston GL; Gleiser CA; Jardine JH
J Am Vet Med Assoc; 1984 Apr; 184(7):814-7. PubMed ID: 6725115
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine.
Van Vechten M; Helfand SC; Jeglum KA
J Vet Intern Med; 1990; 4(4):187-91. PubMed ID: 2401965
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma.
Myers NC; Moore AS; Rand WM; Gliatto J; Cotter SM
J Vet Intern Med; 1997; 11(6):333-9. PubMed ID: 9470157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
